You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Imaging and tumor characteristics with percentage distribution per SUV max category

From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

  N (%) Pretreatment PET SUVmax
   SUVmax < 5 SUVmax ≥ 5 p
All patients 95 40 55 ns
Histology     
Squamous 38 (40%) 8 (20%) 30 (54.5%) .046
Adenocarcinoma 33 (34.7%) 21 (52.5%) 12 (21.8%)  
NSCLC NOS 24 (25.3%) 11 (27.5%) 13 (23.7%)  
Tumor Size [median (range)] 2.15 (0.8-5.0) cm 1.95 (0.9-5.0) cm 2.4 (0.8-4.8) cm .022
T Stage     
1a 46 (48.4%) 27 (67.5%) 19 (34.5%) .013
1b 30 (31.6%) 7 (17.5%) 23 (41.8%)  
2a 19 (20%) 6 (15%) 13 (23.7%)  
  1. Tumor demographics and SUVmax distributions showing tendency for squamous cell histology and larger size to be of increasing SUVmax.